Khiron Life Sciences Corp. completes qualifying transaction

1 minute read
18 May 2018
Client work

On May 18, 2018, Khiron Life Sciences Corp., a Canadian integrated medical cannabis company with core operations in Colombia, announced the closing of its previously announced qualifying transaction. Pursuant to the transaction, a subsidiary of Adent Capital Corp. amalgamated with Khiron which constituted Adent's qualifying transaction.

Gowling WLG advised Khiron in this transaction with a team that included Peter Simeon, Marek Lorenc and Josh Rosen.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related Insights & Resources

View all insights Related Insights & Resources
Female sitting at a desk working on computer Articles
18 April 2024 Alberta revises reporting process for privacy breaches in the private sector
fraud banking credit card Articles
18 April 2024 Exploring the SCC's ruling on the application of the fraud exception to letters of credit: Insights from Eurobank Ergasias S.A. v. Bombardier inc.
Articles
18 April 2024 The Canadian Mortgage Charter: a 2024 Uplift
Download or print PDF